• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pertussis - Pipeline Review, H2 2012 Product Image

Pertussis - Pipeline Review, H2 2012

  • ID: 2245097
  • September 2012
  • 62 pages
  • Global Markets Direct

Pertussis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pertussis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pertussis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pertussis. Pertussis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pertussis.
- A review of the Pertussis products under development by companies and universities/research institutes based on information derived from company and READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Pertussis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Pertussis 8
Pertussis Therapeutics under Development by Companies 10
Pertussis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Pertussis Therapeutics – Products under Development by Companies 16
Pertussis Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Pertussis Therapeutics Development 18
Sanofi-Aventis 18
GlaxoSmithKline plc 19
Merck & Co., Inc. 20
Takeda Pharmaceutical Company Limited 21
Novartis Vaccines and Diagnostics, Inc. 22
LG Life Sciences, Ltd 23
Panacea Biotec Limited 24
Pertussis – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
TdaP Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Act-HIB® reconstituted with TRIPACEL® - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Tdap Vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Tdap - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK-217744 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
DTP-HepB-Polio-Hib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Quadracel - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DtwP-HB-Hib (liq) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
DTP-HepB/Hib Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
V419 + Prevnar 13 + RotaTeq - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
Hexaxim - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Pentavalent DTwP-HepB-Hib Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
KD-332 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Easysix - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TAK-361S - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Acellular Pertussis Vaccine + Tetanus-Diphtheria Booster Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Pertussis Therapeutics – Drug Profile Updates 51
Pertussis Therapeutics – Discontinued Products 54
Pertussis Therapeutics - Dormant Products 55
Pertussis – Product Development Milestones 56
Featured News & Press Releases 56
Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 56
Jul 08, 2011: GSK Receives FDA Approval For BOOSTRIX To Help Prevent Whooping Cough In Adults 65 Years And Older 56
Apr 11, 2011: Arbor Pharmaceuticals Acquires Erythromycin Products From Abbott Laboratories 57
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 57
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 58
Jan 30, 2008: GlaxoSmithKline Launches Two New Innovative Vaccines 58
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 59
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 59
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 60
May 03, 2005: GlaxoSmithKline's Boostrix Approved By FDA For Adolescents Against Pertussis 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Number of Products Under Development for Pertussis, H2 2012 8
Products under Development for Pertussis – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Sanofi-Aventis, H2 2012 18
GlaxoSmithKline plc, H2 2012 19
Merck & Co., Inc., H2 2012 20
Takeda Pharmaceutical Company Limited, H2 2012 21
Novartis Vaccines and Diagnostics, Inc., H2 2012 22
LG Life Sciences, Ltd, H2 2012 23
Panacea Biotec Limited, H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Pertussis Therapeutics – Drug Profile Updates 51
Pertussis Therapeutics – Discontinued Products 54
Pertussis Therapeutics – Dormant Products 55

List of Figures
Number of Products under Development for Pertussis, H2 2012 8
Products under Development for Pertussis – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos